GlaxoSmithKline Cash and Equivalents vs Current Assets Analysis

Trend analysis of GlaxoSmithKline PLC ADR balance sheet accounts such as Other Current Liabilities of 15 B or Total Current Liabilities of 11.2 B provides information on GlaxoSmithKline PLC's total assets, liabilities, and equity, which is the actual value of GlaxoSmithKline PLC ADR to its prevalent stockholders. By breaking down trends over time using GlaxoSmithKline PLC balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Total Assets Non Current Assets Total

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

About GlaxoSmithKline Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of GlaxoSmithKline PLC ADR at a specified time, usually calculated after every quarter, six months, or one year. GlaxoSmithKline PLC Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of GlaxoSmithKline PLC and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which GlaxoSmithKline currently owns. An asset can also be divided into two categories, current and non-current.

GlaxoSmithKline PLC Balance Sheet Chart

GlaxoSmithKline PLC Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how GlaxoSmithKline PLC ADR uses and utilizes its capital. It also shows what exactly a company owns and owes.

At this time, GlaxoSmithKline PLC's Short Term Investments are quite stable compared to the past year. Property Plant And Equipment Gross is expected to rise to about 21.2 B this year, although the value of Total Current Liabilities will most likely fall to about 11.2 B.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of GlaxoSmithKline PLC assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in GlaxoSmithKline PLC ADR books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on GlaxoSmithKline PLC balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of GlaxoSmithKline PLC ADR are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from GlaxoSmithKline PLC's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into GlaxoSmithKline PLC ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

At this time, GlaxoSmithKline PLC's Selling General Administrative is quite stable compared to the past year. Discontinued Operations is expected to rise to about 12.7 B this year, although Enterprise Value Over EBITDA will most likely fall to 7.90.

	2021	2022	2023	2024 (projected)
Interest Expense	784M	879M	775M	502.2M
Depreciation And Amortization	2.6B	2.4B	2.3B	1.2B

Interest Expense Depreciation And Amortization

GlaxoSmithKline PLC fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Capital Stock	Short Term Debt	Common Stock	Retained Earnings	Intangible Assets
Total Assets		0.92	-0.32	0.89	0.5	0.89	0.9	0.77	0.61	0.99	0.37	0.59	0.22	0.79	-0.07	0.95	0.95	0.77	0.97	0.32	0.91	0.7	0.71	0.7	0.12	0.94
Short Long Term Debt Total	0.92		-0.31	0.83	0.41	0.88	0.98	0.71	0.65	0.9	0.34	0.56	0.02	0.7	-0.15	0.91	0.9	0.81	0.91	0.23	0.87	0.73	0.87	0.73	0.03	0.82
Other Current Liab	-0.32	-0.31		-0.33	0.29	-0.11	-0.36	-0.59	0.0	-0.38	-0.26	0.15	0.24	-0.03	0.31	-0.36	-0.21	-0.3	-0.36	0.61	-0.06	0.22	-0.38	0.22	0.26	-0.42
Total Current Liabilities	0.89	0.83	-0.33		0.3	0.89	0.83	0.85	0.45	0.87	0.49	0.52	0.16	0.7	0.05	0.83	0.94	0.74	0.94	0.36	0.87	0.71	0.72	0.71	-0.07	0.77
Total Stockholder Equity	0.5	0.41	0.29	0.3		0.27	0.43	0.1	0.19	0.49	0.2	0.42	0.77	0.77	0.39	0.29	0.35	0.04	0.31	0.56	0.48	0.33	0.25	0.33	0.88	0.51
Property Plant And Equipment Net	0.89	0.88	-0.11	0.89	0.27		0.83	0.73	0.74	0.84	0.33	0.66	-0.02	0.6	-0.12	0.91	0.97	0.88	0.94	0.43	0.93	0.92	0.71	0.92	-0.2	0.73
Net Debt	0.9	0.98	-0.36	0.83	0.43	0.83		0.7	0.5	0.89	0.37	0.46	0.08	0.72	-0.09	0.87	0.87	0.74	0.89	0.24	0.82	0.65	0.9	0.65	0.08	0.82
Accounts Payable	0.77	0.71	-0.59	0.85	0.1	0.73	0.7		0.45	0.77	0.55	0.4	0.01	0.43	-0.1	0.74	0.77	0.78	0.82	0.03	0.67	0.53	0.59	0.53	-0.23	0.74
Cash	0.61	0.65	0.0	0.45	0.19	0.74	0.5	0.45		0.56	0.1	0.73	-0.24	0.31	-0.37	0.68	0.64	0.74	0.61	0.08	0.72	0.77	0.37	0.77	-0.18	0.48
Non Current Assets Total	0.99	0.9	-0.38	0.87	0.49	0.84	0.89	0.77	0.56		0.31	0.5	0.22	0.76	-0.12	0.94	0.92	0.73	0.95	0.28	0.85	0.63	0.7	0.63	0.13	0.97
Non Currrent Assets Other	0.37	0.34	-0.26	0.49	0.2	0.33	0.37	0.55	0.1	0.31		0.61	0.32	0.48	0.66	0.33	0.38	0.42	0.41	0.06	0.51	0.32	0.33	0.32	0.04	0.22
Cash And Short Term Investments	0.59	0.56	0.15	0.52	0.42	0.66	0.46	0.4	0.73	0.5	0.61		0.21	0.65	0.35	0.57	0.63	0.6	0.58	0.3	0.83	0.75	0.32	0.75	0.09	0.35
Common Stock Total Equity	0.22	0.02	0.24	0.16	0.77	-0.02	0.08	0.01	-0.24	0.22	0.32	0.21		0.59	0.68	0.03	0.11	-0.19	0.08	0.57	0.2	0.01	-0.12	0.01	0.77	0.25
Common Stock Shares Outstanding	0.79	0.7	-0.03	0.7	0.77	0.6	0.72	0.43	0.31	0.76	0.48	0.65	0.59		0.42	0.63	0.72	0.38	0.69	0.46	0.79	0.51	0.54	0.51	0.53	0.69
Short Term Investments	-0.07	-0.15	0.31	0.05	0.39	-0.12	-0.09	-0.1	-0.37	-0.12	0.66	0.35	0.68	0.42		-0.18	-0.05	-0.22	-0.09	0.42	0.13	0.0	-0.09	0.0	0.42	-0.18
Non Current Liabilities Total	0.95	0.91	-0.36	0.83	0.29	0.91	0.87	0.74	0.68	0.94	0.33	0.57	0.03	0.63	-0.18		0.94	0.87	0.97	0.25	0.87	0.71	0.71	0.71	-0.12	0.88
Inventory	0.95	0.9	-0.21	0.94	0.35	0.97	0.87	0.77	0.64	0.92	0.38	0.63	0.11	0.72	-0.05	0.94		0.84	0.98	0.4	0.94	0.82	0.7	0.82	-0.08	0.82
Other Stockholder Equity	0.77	0.81	-0.3	0.74	0.04	0.88	0.74	0.78	0.74	0.73	0.42	0.6	-0.19	0.38	-0.22	0.87	0.84		0.85	0.13	0.8	0.78	0.59	0.78	-0.4	0.64
Total Liab	0.97	0.91	-0.36	0.94	0.31	0.94	0.89	0.82	0.61	0.95	0.41	0.58	0.08	0.69	-0.09	0.97	0.98	0.85		0.31	0.91	0.74	0.75	0.74	-0.11	0.88
Property Plant And Equipment Gross	0.32	0.23	0.61	0.36	0.56	0.43	0.24	0.03	0.08	0.28	0.06	0.3	0.57	0.46	0.42	0.25	0.4	0.13	0.31		0.43	0.54	0.18	0.54	0.3	0.26
Total Current Assets	0.91	0.87	-0.06	0.87	0.48	0.93	0.82	0.67	0.72	0.85	0.51	0.83	0.2	0.79	0.13	0.87	0.94	0.8	0.91	0.43		0.88	0.65	0.88	0.06	0.72
Capital Stock	0.7	0.73	0.22	0.71	0.33	0.92	0.65	0.53	0.77	0.63	0.32	0.75	0.01	0.51	0.0	0.71	0.82	0.78	0.74	0.54	0.88		0.55	1.0	-0.14	0.49
Short Term Debt	0.71	0.87	-0.38	0.72	0.25	0.71	0.9	0.59	0.37	0.7	0.33	0.32	-0.12	0.54	-0.09	0.71	0.7	0.59	0.75	0.18	0.65	0.55		0.55	-0.03	0.65
Common Stock	0.7	0.73	0.22	0.71	0.33	0.92	0.65	0.53	0.77	0.63	0.32	0.75	0.01	0.51	0.0	0.71	0.82	0.78	0.74	0.54	0.88	1.0	0.55		-0.14	0.49
Retained Earnings	0.12	0.03	0.26	-0.07	0.88	-0.2	0.08	-0.23	-0.18	0.13	0.04	0.09	0.77	0.53	0.42	-0.12	-0.08	-0.4	-0.11	0.3	0.06	-0.14	-0.03	-0.14		0.2
Intangible Assets	0.94	0.82	-0.42	0.77	0.51	0.73	0.82	0.74	0.48	0.97	0.22	0.35	0.25	0.69	-0.18	0.88	0.82	0.64	0.88	0.26	0.72	0.49	0.65	0.49	0.2

Click cells to compare fundamentals

GlaxoSmithKline PLC Account Relationship Matchups

GlaxoSmithKline PLC fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	79.7B	80.4B	79.1B	60.1B	59.0B	32.8B
Short Long Term Debt Total	30.5B	27.2B	24.2B	21.0B	18.0B	11.0B
Other Current Liab	755M	765M	958M	2.3B	14.3B	15.0B
Total Current Liabilities	24.1B	22.1B	23.7B	22.8B	21.1B	11.2B
Total Stockholder Equity	12.0B	14.6B	15.1B	10.6B	13.3B	14.0B
Property Plant And Equipment Net	11.3B	11.0B	10.7B	9.6B	10.0B	7.2B
Net Debt	25.8B	20.9B	19.9B	17.3B	15.1B	8.3B
Accounts Payable	14.9B	15.8B	17.6B	16.3B	3.7B	6.2B
Cash	4.7B	6.3B	4.3B	3.7B	2.9B	2.7B
Non Current Assets Total	60.2B	60.2B	60.4B	39.4B	40.4B	20.9B
Non Currrent Assets Other	1.2B	1.1B	1.8B	5.3B	634M	1.1B
Cash And Short Term Investments	4.8B	6.4B	4.3B	7.9B	5.2B	4.0B
Common Stock Shares Outstanding	4.0B	4.0B	3.2B	4.1B	4.1B	2.2B
Liabilities And Stockholders Equity	79.7B	80.4B	79.1B	60.1B	59.0B	32.8B
Non Current Liabilities Total	37.3B	37.5B	34.1B	27.2B	25.1B	14.3B
Inventory	5.9B	6.0B	5.8B	5.1B	5.5B	3.0B
Other Stockholder Equity	5.2B	4.9B	4.9B	5.1B	3.2B	2.9B
Total Liab	61.3B	59.6B	57.8B	50.1B	46.2B	25.5B
Property Plant And Equipment Gross	10.3B	11.0B	10.7B	9.6B	20.2B	21.2B
Total Current Assets	19.5B	20.2B	18.7B	20.8B	18.6B	11.9B
Capital Stock	1.3B	1.3B	1.3B	1.3B	1.3B	1.3B
Short Term Debt	6.9B	3.7B	3.6B	4.0B	2.8B	2.2B
Common Stock	1.3B	1.3B	1.3B	1.3B	1.3B	1.3B
Retained Earnings	5.1B	6.8B	7.9B	4.4B	7.2B	7.6B
Accumulated Other Comprehensive Income	641M	1.6B	642M	(48M)	1.6B	1.7B
Intangible Assets	31.0B	29.8B	30.1B	14.3B	14.8B	11.4B
Other Liab	13.7B	14.1B	13.5B	10.2B	11.7B	14.2B
Long Term Debt	22.6B	23.4B	20.6B	17.0B	14.2B	17.5B
Good Will	10.6B	10.6B	10.6B	7.0B	6.8B	5.3B
Other Current Assets	1.6B	617M	525M	7.7B	561M	533.0M
Property Plant Equipment	11.3B	11.0B	10.7B	9.6B	8.7B	9.7B
Current Deferred Revenue	1.4B	1.8B	1.6B	299M	222M	233.1M
Other Assets	5.1B	5.3B	6.9B	6.9B	7.9B	5.4B
Net Receivables	7.1B	7.3B	8.0B	7.1B	7.4B	6.5B
Net Tangible Assets	(30.1B)	(25.8B)	(25.6B)	(10.8B)	(12.4B)	(13.0B)
Short Long Term Debt	6.7B	3.5B	3.4B	3.8B	2.7B	4.3B

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards GlaxoSmithKline PLC in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, GlaxoSmithKline PLC's short interest history, or implied volatility extrapolated from GlaxoSmithKline PLC options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Other Tools for GlaxoSmithKline Stock

When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.

	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	CEOs Directory Screen CEOs from public companies around the world
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

GlaxoSmithKline Cash and Equivalents vs Current Assets Analysis

About GlaxoSmithKline Balance Sheet Analysis

GlaxoSmithKline PLC Balance Sheet Chart

Total Assets

Total Current Liabilities

GlaxoSmithKline PLC fundamental ratios Correlations

GlaxoSmithKline PLC Account Relationship Matchups

High Positive Relationship

High Negative Relationship

GlaxoSmithKline PLC fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Other Tools for GlaxoSmithKline Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Capital Stock
Non Current Assets Total	+ 0.99	Total Assets
Net Debt	+ 0.98	Short Long Term Debt Total
Total Liab	+ 0.98	Inventory
Total Liab	+ 0.97	Total Assets
Inventory	+ 0.97	Property Plant And Equipment Net

Accounts Payable	- 0.59	Other Current Liab
Intangible Assets	- 0.42	Other Current Liab
Retained Earnings	- 0.4	Other Stockholder Equity
Short Term Debt	- 0.38	Other Current Liab
Non Current Assets Total	- 0.38	Other Current Liab
Short Term Investments	- 0.37	Cash